SeaStar Medical plunges on 433% EPS miss despite 9x revenue surge
Biotech reports $0.80 loss per share versus $0.15 estimate, though customer base expands to 16 hospitals
SeaStar Medical Holding Corporation shares fell sharply after the biotechnology company reported a fourth-quarter loss per share that missed analyst estimates by 433%, overshadowing a ninefold increase in annual revenue that highlighted the company's early-stage commercialization efforts.
The Denver-based company reported an adjusted loss of $0.80 per share for the fourth quarter of 2025, significantly wider than the $0.15 loss that Wall Street had anticipated, according to regulatory filings with the Securities and Exchange Commission. The shortfall comes despite revenue of $420,000 for the quarter, which topped the $300,000 consensus estimate by 68 percent.
The company posted a net loss of $2.9 million for the quarter, an improvement from the $4.4 million loss recorded in the same period a year earlier. For the full year 2025, SeaStar Medical reported revenue of $1.2 million, a dramatic increase from $135,000 in 2024, as it expanded its customer base to 16 hospitals treating patients with acute kidney injury using its QUELIMMUNE™ therapy.
"We continue to make meaningful progress advancing our proprietary Cytosorb™ technology and expanding our commercial footprint," the company stated in its earnings announcement, noting that it had added top-rated children's hospitals to its pediatric AKI customer base during the quarter.
SeaStar Medical ended the year with $12 million in cash, providing what management described as sufficient runway to fund operations through key clinical milestones. The company guided for approximately $2 million in revenue for 2026 and said it expects to complete its NEUTRALIZE-AKI trial by the end of the year.
The biotechnology sector has faced heightened investor scrutiny in recent months as rising interest rates have increased the cost of capital for early-stage companies without near-term profitability. SeaStar Medical, which focuses on developing therapies for chronic kidney disease and acute kidney injury, operates in a competitive market where large pharmaceutical companies are also pursuing treatments for renal conditions.
The company's stock has been volatile, trading at $2.28 at market close, well below its 52-week high of $25.70 but above its 52-week low of $2.09. The shares have a market capitalization of approximately $8.4 million, according to market data. Analysts have maintained a price target of $9.00 on the stock, suggesting significant upside if the company can execute on its clinical development and commercialization strategy.
SeaStar's proprietary technology aims to reduce inflammation and improve renal function without the need for invasive interventions, addressing what the company describes as significant unmet medical needs in the treatment of kidney disease. The successful completion of the NEUTRALIZE-AKI trial could provide critical clinical validation for the company's approach and potentially open the door to broader market adoption.
The company also reported completing enrollment in an FDA-mandated SAVE trial for its QUELIMMUNE therapy during the quarter, a milestone that regulatory observers say is essential for maintaining compliance with agency requirements while generating additional clinical data.
Investors will be watching closely for updates on the NEUTRALIZE-AKI trial timeline and early results from the SAVE study, both of which could serve as significant catalysts for the stock in the coming months. The $12 million cash position provides the company with operational flexibility, though the continued quarterly losses highlight the challenges facing early-stage biotechnology companies as they navigate the lengthy and expensive clinical development process.